National
News
Features
Profiles/Interviews
Local Sports
Yalla Jordan
The Royal wedding
Where to Go
Around Jordan
Cartoon
Podcasts
Global
Football
Middle East
Basketball
Africa
Europe
Americas
Asia
Baseball
Cricket
Australasia
Racing
Rugby
Olympics
Business
Economy
Trade & Industry
Entrepreneurship
Opinion & Analysis
Analysis
Opinion
Lifestyle
Good Food
Health
Fashion
Travel
Culture & Arts
Entertainment
Education
Music
Technology
Gaming
Drive
Reviews
Books
Trending
Odd & Bizarre
Property
Games
Jumble Crossword Daily
Jumble Crossword Sunday
Jumble Daily
Jumble Sunday
Jumble for Kids
TV Jumble
Daily Commuter Crossword
LA Times Daily Crossword
LA Times Sunday Crossword
TV Crossword
Killer Sudoku
Killer Sudoku Pro
Sudoku
Sudoku X
Hitori
Futoshiki
Home
National
News
Features
Profiles/Interviews
Local Sports
Yalla Jordan
The Royal wedding
Where to Go
Around Jordan
Cartoon
Podcasts
Global
REGION & WORLD
Middle East
Africa
Europe
Americas
Asia
Australasia
SPORTS
Football
Basketball
Baseball
Cricket
Racing
Rugby
Olympics
Business
Economy
Trade & Industry
Entrepreneurship
Opinion & Analysis
Analysis
Opinion
Lifestyle
Good Food
Health
Fashion
Travel
Culture & Arts
Entertainment
Education
Music
Technology
Gaming
Drive
Reviews
Books
Trending
Odd & Bizarre
Property
GAMES
Jumble
Jumble Crossword Daily
Jumble Crossword Sunday
Jumble Daily
Jumble Sunday
Jumble for Kids
TV Jumble
Crossword
Daily Commuter Crossword
LA Times Daily Crossword
LA Times Sunday Crossword
TV Crossword
Sudoku
Killer Sudoku
Killer Sudoku Pro
Sudoku
Sudoku X
Hitori
Futoshiki
Breaking News:
Jordan News: Your new online hub for the latest local, global updates
Meet the team
June 6 2023
9:02 AM
E-paper
Newsletter
Subscribe
Sign in
My Account
Sign out
#Hikma
Hikma, Celltrion sign monoclonal antibody licensing agreement
Nov 29,2022
|
All
Hikma’s success story: how to revive industry
Oct 15,2022
|
Opinion
HM stresses importance of pharmaceutical sector to economy at Hikma inaugration
Sep 06,2022
|
News
Hikma, Adalvo agree to commercialize allergic Rhinitis
Aug 31,2022
|
All
Hikma, MPP sign licensing agreement for COVID-19 pill
Jan 21,2022
|
All
Hikma to acquire Custopharm for $375 million
Sep 27,2021
|
News
Hikma announces good 2021 start, reiterates full year guidance
May 01,2021
|
All
.jpg)
.jpg)
